Please login to the form below

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease:

29th January 2020


Company Details

OPEN Health

+44 1628 481112

Contact Website

The Weighbridge
Brewery Courtyard
High Street
United Kingdom

Latest content on this profile

OPEN Health Medical Communications is awarded Medical Affairs Agency of The Year at the Communiqué Awards 2020
We are delighted to announce that OPEN Health Medical Communications was named Medical Affairs Agency of the Year at the virtual 2020 Communiqué Awards ceremony on 02 July 2020.
OPEN Health
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me.
OPEN Health
Candice Subero to Lead Global Marketing for OPEN Health

OPEN Health
The RARE Youth Revolution has begun
OPEN Health are proud to support RARE Revolution Magazine who have launched a dedicated RARE youth online platform powering up the voices of the youth rare disease community.
OPEN Health
Jeff Anderson joins OPEN Health as European Lead for OPEN VIE and Pharmerit

OPEN Health
OPEN Health Webinar - Succeeding with Star Wars Medicine
Summary of their recently published white paper on gene therapy followed by a Q&A session on 12th June 2020. Book now!
OPEN Health